U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07399171) titled 'Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers' on Dec. 24, 2025.
Brief Summary: Primary Objectives:
To demonstrate that HT-4253 improves the amyloid risk profile by transitioning biomarker-positive APOE4 carriers from a positive, high risk APS2 score to a negative, low risk APS2 score.
Secondary Objectives:
* To assess the effects of HT-4253 on tau related blood biomarker progression over the study period.
* To assess the effects of HT-4253 on amyloid related blood biomarker progression over the study period.
* To assess the safety and tolerability of HT-4253 in the UAE popu...